Epinephrine Market to surpass USD 5.2 Billion, Globally At a CAGR 11.0% Forecast by 2028 | Impax Laboratories, Inc., Kaleo, Inc. Mylan N.V., Pfizer, Inc.

𝐀 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐧𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐧𝐨𝐯𝐞𝐥 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐭𝐨 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐚𝐭𝐞 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡

The manufacturers are focused on developing and commercializing innovative drugs and novel drug delivery systems of therapeutic molecules to improve patients’ quality of life and to overcome the clinical shortcomings of commercially available products.

According to the Mayo Clinic, 2016, more than 200,000 cases of anaphylaxis occur annually in the U.S., indicating the higher number of potential patient pool in the region. Also, the World Allergy Organization, in 2015 estimated that up to two percent of the global population, accounting for 150 million people are expected to experience anaphylaxis during their lifetime.

𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐚𝐭𝐞𝐫𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/request-sample/2401

In July 2018, INSYS Therapeutics, Inc. demonstrated the results of early clinical trial for its investigational epinephrine nasal spray, as a potential needle-free, non-invasive, and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. The investigators also highlighted the benefits of effective needleless alternative delivery options showing rapid drug absorption. In August 2018, FDA granted Fast Track designation for the epinephrine nasal spray.

Furthermore, in April 2018, Aquestive Therapeutics initiated the Phase-1 clinical trials for its complex molecule programs- AQST-108 epinephrine molecule for anaphylaxis, which is administered via sublingual route.

Browse 36 Market Data Tables and 34 Figures spread through 175 Pages and in-depth TOC on “Epinephrine Market”- Global Forecast to 2026, by Product Type (Auto-injector, Prefilled Syringes, and Ampoules and Vials), by Application (Anaphylaxis, Cardiac Arrest, Superficial Bleeding, Respiratory Disorders and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

𝐓𝐨 𝐊𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/2401

The market players are focused on strategic collaborations to provide products freely at retail outlets, considering shortages in supply of competitors' epinephrine auto-injectors. For instance, in September 2018, Walgreens and Kaleo entered into partnership under which AUVI-Q would be available at all pharmacies across the U.S. This step will aid in increasing accessibility of epinephrine auto-injector.

Also, in July 2018, Adamis Pharmaceuticals announced that Sandoz, a Novartis division, bought the rights to market its epinephrine device, a pre-filled 0.3 mg-dose syringe called Symjepi in the U.S. market. In 2015, Impax Laboratories, Inc. acquired Tower Holdings, Inc. including subsidiaries Amedra Pharmaceuticals LLC. Amedra is manufacturer of the Adrenaclick (epinephrine injection) auto-injector.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐄𝐩𝐢𝐧𝐞𝐩𝐡𝐫𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:

• The global epinephrine market is expected to exhibit a CAGR of 11.0% during the forecast period, owing to the approval of cost-effective generic auto-injectors in the market, and strategic support of companies and government agencies for increasing generic epinephrine adoption.

• Among product type, the auto-injector segment held a dominant position in the epinephrine market in 2018 owing to the wide use of the product in auto-injectable form due to ease of administration and rapid onset of action.

• Among application, the anaphylaxis segment held a dominant position in the epinephrine market in 2018, owing to high incidence rate of anaphylaxis due to consumption of food products such as peanut or tree nut in children and increasing supplemental new drug application in infants.

• Companies operating in the global epinephrine market include Mylan N.V., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals Corporation, Bausch Health Companies, ALK- Abello A/S.

𝐓𝐨 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐚𝐧𝐝 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 -https://www.coherentmarketinsights.com/insight/buy-now/2401

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.